Eisai Will Highlight Real-World Experience Data with Lecanemab at 2025 American Academy of Neurology Meeting
Data on use of lecanemab in real world clinical settings will come from a neurologic case series review and a retrospective chart review of long-term use, both in early AD.
Eisai Inc. will present the latest findings from its neurology portfolio at the American Academy of Neurology (AAN) Annual Meeting, scheduled to take place in San Diego, California, and virtually from April 5–9, 2025, the company announced.1
©Eisai, Inc.
Data to watch for will including findings from real-world experience and continued maintenance dosing of lecanemab2 (Leqembi). Lecanemab is a dual-acting, anti-amyloid beta (Aβ) protofibril antibody approved in 20233 for the treatment of early Alzheimer disease (AD). Eisai’s presentations on lecanemab will include 2 oral presentations, 6 posters, and 2 non-CME educational sessions targeting communication with patients and care partners about AD and antiamyloid therapy.
Poster presentations
Session P1: Alzheimer disease diagnostics and biomarkers
Sat April 5, 11:45 AM–12:45 PM PT
- Poster #003 The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease (Abstract ID: 4158)
Session P12: Alzheimer’s Treatment: Aging, Dementia, and Behavioral Neurology
Wed April 9, 11:45 AM–12:45 PM PT
- Poster #012 Real-World Experience with Long-Term Lecanemab Treatment: A Retrospective Chart Review in Early Alzheimer’s Disease (Abstract ID: 3274)
- Poster #008 Lecanemab in Clinical Practice: Real-World Treatment Outcomes from a Retrospective Neurological Clinic Case Series Review in Early Alzheimer’s Disease (Abstract ID: 4827)
- Poster #006 Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease (Abstract ID: 4653)
- Poster #019 Lecanemab Treatment in Real-World Settings in the United States (Abstract ID: 2639)
- Poster #001 Cerebellar ARIA in a Patient with an APP Duplication Treated with Lecanemab (Abstract ID: 1555)
Oral presentations: Maintenance dosing and cost effectiveness
Tues April 8, 1:00-2:30 PM PT
- 1:00–1:08 PM Cost-Effectiveness of Lecanemab for the Treatment of Early Alzheimer’s Disease: A Canadian Societal Perspective (Oral Presentation #001 / Abstract ID: 4924)
- 2:12–2:20 PM Lecanemab Maintenance Dosing in Early Alzheimer’s Disease: Support for Continued Dosing from Clinical, Pharmacology, and Modeling Data (Oral Presentation #007 / Abstract ID: 3687)
Industry therapeutic updates
Sun April 6
- Talking with Patients and Care Partners About Early AD Treatment: Communicating the Rationale for Early, Ongoing Therapy (11:45 AM–12:45 PM PT)
Mon April 7
- Driving Change for Anti-Amyloid Therapy Implementation: Overcoming Challenges Across Practice Settings (11:45 AM–12:45 PM PT)
Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that selectively targets aggregated soluble (protofibril) and insoluble forms of Aβ. Lecanemab, approved in multiple countries as well as the US, has demonstrated statistically significant reductions in cognitive decline in clinical trials.
The Clarity AD phase 3 trial4 established efficacy of lecanemab, demonstrating a 27% reduction in clinical decline on the Clinical Dementia Rating Sum of Boxes at 18 months compared to placebo (P <.001). On the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), lecanemab-treated participants showed a 37% functional improvement compared to placebo (P <.001). The most common adverse events (>10%) included infusion reactions, ARIA-H (cerebral microhemorrhages, macrohemorrhages, superficial siderosis), ARIA-E (edema/effusion), headache, and falls.
Ongoing lecanemab trials include AHEAD 3-45,5 a phase 3 trial evaluating preclinical AD patients, and the Tau NexGen study, assessing its role in dominantly inherited AD.
